Altimmune Inc.’s ability to start clinical trials for its coronavirus vaccine candidate now lies in the hands of regulators.
The Gaithersburg biotech has submitted its investigational new drug application for its intranasal Covid-19 vaccine, AdCovid, to the Food and Drug Administration, the company said Wednesday. An approval would allow the company to initiate a phase 1 study of the candidate.
Altimmune (NASDAQ: ALT) is on track to kick off that trial in 2020 and report data in the first quarter of 2021, said President and CEO Vipin Garg in a statement. Based on that data, the company “would plan to move swiftly” into a phase 2 clinical trial next year, he told us previously.
Read the full article at: www.bizjournals.com





Chris Frew





Latest posts by Chris Frew (see all)
- Gyroscope Therapeutics, which has operations in King of Prussia, raises $148M - March 31, 2021
- TCR² Therapeutics Acquires Cell Therapy Manufacturing Facility & New VP of Technical Operations, Aaron Vernon - March 29, 2021
- Frederick Based Biotech Law Firm McBee Moore & Vanik IP, LLC Celebrates Five Years - February 18, 2021
- Heather Mudrick Joins Workforce Genetics to Lead Clinical Search Practice - February 12, 2021
- RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC - February 4, 2021